Czyżewski Wojciech, Kus-Budzynska Klaudia, Sobstyl Jan, Sojka Michał, Litak Jakub, Szaliński Tomasz, Jeżewski Mateusz P, Turek Michał, Chaurasia Bipin, Mandat Tomasz, Torres Kamil, Staśkiewicz Grzegorz
Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Department of Didactics and Medical Simulation, Medical University of Lublin, Lublin, Poland.
Ann Med Surg (Lond). 2025 Jul 18;87(9):5743-5756. doi: 10.1097/MS9.0000000000003607. eCollection 2025 Sep.
Chimeric antigen receptor T (CAR-T) therapy for glioblastoma involves critically evaluating progress, effectiveness, and challenges. By examining current research, clinical trials, and emerging trends, the analysis highlights clinical outcomes and biological insights that demonstrate the therapeutic potential of CAR-T cells, along with technological innovations aimed at enhancing their efficacy and safety. However, significant obstacles such as overcoming the blood-brain barrier and managing severe side effects like cytokine release syndrome remain.
A systematic search using PubMed, Scopus, Web of Science, and Google Scholar from 2010 to 2024 has been conducted. Search terms included "CAR-T," "glioblastoma," "immunotherapy," and "clinical trials." Inclusion criteria were English-language studies focusing on CAR-T applications in glioblastoma. Exclusion criteria included non-peer-reviewed articles and preclinical-only studies.
The findings suggest promising prospects for integrating CAR-T cell therapy into existing glioblastoma treatment paradigms, emphasizing the need for continued research and innovation in genetic engineering and combination therapies to fully realize the potential of CAR-T cells in transforming glioblastoma treatment.
CAR-T cell therapy offers groundbreaking potential in transforming glioblastoma treatment by harnessing the immune system to target and destroy cancer cells.
胶质母细胞瘤的嵌合抗原受体T（CAR-T）细胞疗法涉及对进展、有效性和挑战进行严格评估。通过审视当前的研究、临床试验和新趋势，该分析突出了临床结果和生物学见解，这些结果和见解展示了CAR-T细胞的治疗潜力，以及旨在提高其疗效和安全性的技术创新。然而，仍存在重大障碍，如克服血脑屏障和处理细胞因子释放综合征等严重副作用。
对2010年至2024年期间使用PubMed、Scopus、Web of Science和谷歌学术进行了系统检索。检索词包括“CAR-T”、“胶质母细胞瘤”、“免疫疗法”和“临床试验”。纳入标准为聚焦于CAR-T在胶质母细胞瘤中应用的英文研究。排除标准包括非同行评审文章和仅为临床前研究。
研究结果表明将CAR-T细胞疗法整合到现有胶质母细胞瘤治疗模式中有广阔前景，强调在基因工程和联合疗法方面需要持续研究和创新，以充分实现CAR-T细胞在改变胶质母细胞瘤治疗方面的潜力。
CAR-T细胞疗法通过利用免疫系统靶向并摧毁癌细胞，在改变胶质母细胞瘤治疗方面具有开创性潜力。
